
MTVA Stock Forecast & Price Target
MTVA Analyst Ratings
Bulls say
MetaVia is a clinical-stage biotechnology company with a promising pipeline targeting cardiometabolic diseases, specifically MASH and obesity. The company's novel compound, Vanoglipel (DA-1241), has shown potential as a standalone or combination therapy for both MASH and Type 2 Diabetes. In addition, the company has reported positive data for its obesity treatment, DA-1726, and has a strong financial position with $13.7 million in cash as of March 31, 2026. Risks for investors include the potential for disappointing data, failure to identify a treatment combination for DA-1241, and delays in development timelines. Overall, MetaVia has a positive outlook with multiple potential growth drivers in its pipeline.
Bears say
MetaVia is in a critical phase of development, with key data events expected in 4Q26 for both the Phase 1 Part 3 program for DA-1726 and the FDA end-of-Phase 2 meeting for vanoglipel. However, concerns remain around the potential differentiation of DA-1726's effects and the company's financials, with a heavy reliance on the upcoming data and potential need for further financing. It will be crucial to assess the data in the context of competitive peers to determine the likelihood of success and potential for market differentiation.
This aggregate rating is based on analysts' research of NeuroBo Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MTVA Analyst Forecast & Price Prediction
Start investing in MTVA
Order type
Buy in
Order amount
Est. shares
0 shares